Trial Outcomes & Findings for Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer (NCT NCT00963872)
NCT ID: NCT00963872
Last Updated: 2017-12-28
Results Overview
Efficacy of the pre-incubation of one of two umbilical cord blood (UCB) units with C3a as part of a unrelated donor double UCB nonmyeloablative transplantation in patients with high-risk hematological malignancies.
TERMINATED
PHASE1/PHASE2
31 participants
Day 180
2017-12-28
Participant Flow
Subjects were recruited at the time of clinic visit or hospitalization. Patients that were considered for umbilical cord transplant were approached with the study.
Subjects that were eligible for umbilical cord transplant were considered for the study.
Participant milestones
| Measure |
Complement Fragment 3A - Small Cell Dose
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Overall Study
STARTED
|
25
|
6
|
|
Overall Study
COMPLETED
|
24
|
5
|
|
Overall Study
NOT COMPLETED
|
1
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Baseline characteristics by cohort
| Measure |
Complement Fragment 3A - Small Cell Dose
n=25 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=6 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
Total
n=31 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
19 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
24 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
6 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
|
Age, Continuous
|
55 years
STANDARD_DEVIATION 13.0 • n=5 Participants
|
50 years
STANDARD_DEVIATION 15.7 • n=7 Participants
|
54 years
STANDARD_DEVIATION 13.4 • n=5 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
20 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
25 participants
n=5 Participants
|
6 participants
n=7 Participants
|
31 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Day 180Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Efficacy of the pre-incubation of one of two umbilical cord blood (UCB) units with C3a as part of a unrelated donor double UCB nonmyeloablative transplantation in patients with high-risk hematological malignancies.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Number of Patients With the Complement 3a (C3a) Unit Predominating
|
9 participants
|
5 participants
|
SECONDARY outcome
Timeframe: Day 42Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Achieving 500 neutrophils/uL by day 42.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Neutrophil Engraftment
|
22 participants
|
5 participants
|
SECONDARY outcome
Timeframe: Day 28Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Percentage of donor DNA present in the peripheral blood
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Donor Chimerism in Blood
|
92 percentage of donor DNA
Standard Deviation 15
|
96 percentage of donor DNA
Standard Deviation 8
|
SECONDARY outcome
Timeframe: Day 0 through Day 100Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Development of graft-versus-host disease through day 100.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Incidence of Grades II-IV Graft-vs-host Disease
|
8 participants
|
1 participants
|
SECONDARY outcome
Timeframe: Day 180Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Deaths not due to relapse.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Non-Relapse Mortality
|
3 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 360Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Survival (alive) from transplantation to last follow-up.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Overall Survival
|
14 participants
|
5 participants
|
SECONDARY outcome
Timeframe: Day 21Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Percentage of donor DNA in the bone marrow.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Bone Marrow Chimerism
|
84 percentage of donor DNA
Standard Deviation 25
|
89 percentage of donor DNA
Standard Deviation 23
|
SECONDARY outcome
Timeframe: Day 360Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Patients who developed chronic graft-versus-host disease.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Chronic Graft-Versus-Host Disease
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 360Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Patients who developed disease relapse after transplantation.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Relapse of Disease
|
10 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 360Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Patients who developed disease progression after transplantation.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Disease Progression
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 180Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Number of patients with \>20,000 platelets/uL by day 180
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Platelet Recovery
|
19 participants
|
5 participants
|
SECONDARY outcome
Timeframe: Day 60Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Percentage of donor DNA present in the peripheral blood
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Donor Chimerism in Blood
|
91 percentage of donor DNA
Standard Deviation 23
|
97 percentage of donor DNA
Standard Deviation 4
|
SECONDARY outcome
Timeframe: 0 to 100 daysPopulation: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Development of graft-versus-host disease by day 100.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Incidence of Grades III-IV Graft-vs-host Disease
|
2 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 360Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Deaths not due to relapse.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Non-relapse Mortality
|
3 participants
|
0 participants
|
SECONDARY outcome
Timeframe: 720 daysPopulation: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Survival (alive) from transplantation to last follow-up at day 720.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Overall Survival at Day 720
|
13 participants
|
5 participants
|
SECONDARY outcome
Timeframe: Day 720Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Patients who developed disease relapse after transplantation.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Relapse of Disease
|
11 participants
|
1 participants
|
SECONDARY outcome
Timeframe: Day 720Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Patients who developed disease progression after transplantation.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Disease Progression
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 100Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Percentage of donor DNA in the bone marrow.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Donor Chimerism
|
90 percentage of donor DNA
Standard Deviation 22
|
94 percentage of donor DNA
Standard Deviation 19
|
SECONDARY outcome
Timeframe: Day 180Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Percentage of donor DNA in the bone marrow.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Donor Chimerism
|
99 percentage of donor DNA
Standard Deviation 3
|
100 percentage of donor DNA
Standard Deviation 0
|
SECONDARY outcome
Timeframe: Day 360Population: Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.
Percentage of donor DNA in the bone marrow.
Outcome measures
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 Participants
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Donor Chimerism
|
93 percentage of donor DNA
Standard Deviation 19
|
100 percentage of donor DNA
Standard Deviation 0
|
Adverse Events
Complement Fragment 3A - Small Cell Dose
Complement Fragment A - Larger Cell Dose
Serious adverse events
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 participants at risk
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 participants at risk
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Blood and lymphatic system disorders
Blood and lymphatic disorders- Other
|
41.7%
10/24 • Number of events 10 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Blood and lymphatic system disorders
Leukocytosis
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Gastrointestinal disorders
Diarrhea
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Gastrointestinal disorders
Nausea
|
4.2%
1/24 • Number of events 2 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Gastrointestinal disorders
Pancreatitis
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Gastrointestinal disorders
Stomach pain
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Gastrointestinal disorders
Upper gastrointestinal hemorrhage
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Gastrointestinal disorders
Vomiting
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
General disorders
Death NOS
|
8.3%
2/24 • Number of events 2 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
General disorders
Fever
|
20.8%
5/24 • Number of events 5 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
General disorders
Infusion related reaction
|
0.00%
0/24 • 100 days after umbilical cord blood transplant
|
20.0%
1/5 • Number of events 1 • 100 days after umbilical cord blood transplant
|
|
Infections and infestations
Catheter related infection
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Infections and infestations
Lung infection
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
20.0%
1/5 • Number of events 1 • 100 days after umbilical cord blood transplant
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/24 • 100 days after umbilical cord blood transplant
|
20.0%
1/5 • Number of events 1 • 100 days after umbilical cord blood transplant
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Nervous system disorders
Seizure
|
8.3%
2/24 • Number of events 2 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Psychiatric disorders
Confusion
|
8.3%
2/24 • Number of events 2 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Renal and urinary disorders
Hematuria
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Renal and urinary disorders
Renal and urinary disorders- Other
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Respiratory, thoracic and mediastinal disorders
Adult respiratory distress syndrome
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
40.0%
2/5 • Number of events 2 • 100 days after umbilical cord blood transplant
|
|
Respiratory, thoracic and mediastinal disorders
Bronchopulmonary hemorrhage
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/24 • 100 days after umbilical cord blood transplant
|
20.0%
1/5 • Number of events 1 • 100 days after umbilical cord blood transplant
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic plan
|
4.2%
1/24 • Number of events 1 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/24 • 100 days after umbilical cord blood transplant
|
20.0%
1/5 • Number of events 1 • 100 days after umbilical cord blood transplant
|
Other adverse events
| Measure |
Complement Fragment 3A - Small Cell Dose
n=24 participants at risk
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
|
Complement Fragment A - Larger Cell Dose
n=5 participants at risk
Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
|
|---|---|---|
|
Skin and subcutaneous tissue disorders
Rash
|
12.5%
3/24 • Number of events 3 • 100 days after umbilical cord blood transplant
|
0.00%
0/5 • 100 days after umbilical cord blood transplant
|
|
Blood and lymphatic system disorders
Hypertension
|
100.0%
24/24 • Number of events 24 • 100 days after umbilical cord blood transplant
|
80.0%
4/5 • Number of events 4 • 100 days after umbilical cord blood transplant
|
|
Cardiac disorders
Sinus tachycardia
|
8.3%
2/24 • Number of events 2 • 100 days after umbilical cord blood transplant
|
20.0%
1/5 • Number of events 1 • 100 days after umbilical cord blood transplant
|
|
Nervous system disorders
Neurologic disorder
|
16.7%
4/24 • Number of events 4 • 100 days after umbilical cord blood transplant
|
20.0%
1/5 • Number of events 1 • 100 days after umbilical cord blood transplant
|
|
Cardiac disorders
Sinus bradycardia
|
29.2%
7/24 • Number of events 7 • 100 days after umbilical cord blood transplant
|
40.0%
2/5 • Number of events 2 • 100 days after umbilical cord blood transplant
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place